National Pharmaceuticals Pricing Policy: A Review
Keywords:
.Abstract
Like many other developing and a few developed countries, India also partly depends on pharmaceutical companies for its economic growth. Realizing the concept along with the need to provide accessible and affordable essential drugs to the citizens, especially those of economical weaker section, many drugs or pharmaceutical policies were formulated in India. Such policies ensure continuous availability of safe and effective essential medicines, especially in the public sector and quality, safety and efficacy of human and veterinary drugs inline with internationally acceptable standards while ensuring appropriate regulation and control, latest being the National Pharmaceutical Pricing Policy (NPPA), 2013, the focus of which is to include more drugs under NLEP, decrease in cost of medicines, providing generic medicines, etc. The use of the international non-proprietary name (INN), or generic name, is a recognized strategy to reduce medicine costs and expenditure. The policy though up to certain level provided the relief in the cost of essential medicines but still major areas were still untouched by the policy. This article deals with the drawback of the pharmaceutical policies in our country. Also the major problems being faced by the doctors who are part of government healthcare system and a vision of how to deal with it or what more can be added in such policies to provide the smooth and effective basic healthcare to the community.
References
pricing policy, 2012 .The Gazette of India, Part 1,
Section 1; 2012.
2. Government of India. Drug policy, Ministry of
Chemicals & Fertilizers. India 1986 Government
notifies new drug pricing policy, cheaper drugs on
way. Financial Express 13 Dec, 2012. Available at:
http://www.financialexpress.com/news/governmen
t-notifies-new-drug-pricing- policy cheaper
[accessed on Oct 1, 2016].
3. Government of India. Drug policy, Ministry of
Chemicals & Fertilizers. India 2013.
4. Golechha M. Healthcare agenda for the Indian
government. Indian J Med Res 2015; 141: 151-53.
5. Government of India. National health policy draft.
Ministry of Health and Family Welfare, Government
of India, New Delhi. 2014.
6. Government of India. Department of
Pharmaceuticals. Ministry of Chemicals &
Fertilizers. Annual Report 2015-16.
7. Danzon M, Chao L. Does regulation drive out
competition in pharmaceutical markets? Journal of
Law and Economics 2011; 43(2): 311-58.
8. Danzon M, Wang Y, Wang L. The impact of price
regulation on the launch delay of new drugsevidence
from twenty five major markets in 1990s.
Health Economics 2005; 14(3); 269-92.
9. Danzon M, Ketcham D. Reference pricing of
pharmaceuticals for medicare: Evidence from
Germany and the Netherlands and New Zealand.
Frontiers in health policy research 2003: 7; 1-54.
10. Acemoglu D, Linn J. Market size in innovation:
Theory and evidence from the pharmaceutical
industry. National Bureau of Economic Research
2003; 119: 1049-90.
11. World Health Organization. Global health
observatory data 2016 (Internet). (cited Oct 3,
2016). Available from: http://www.who.int/gho/
healthfinancing/out_out_pocket_expenditure/en/&
rqid=e1ngbu7W&geid=he2010/en/
12. Andriollo O, Machuron L, Videau JY et al. Supplies
for humanitarian aid and development countries:
The quality of essential multisource drugs. S.T.P.
Pharma Pratiques1998; 8: 137-55.
13. Food & Drug Administration, Generic Drugs:
Questions and Answers. Jan 12, 2010. [Retrieved
Oct 3, 2016]. Available from: http://www.fda.gov/
Drugs/ResourcesForYou/Consumers/BuyingUsingM
edicineSafely/UnderstandingGenericDrugs/ucm167
991.htm.
14. World Health Organization. WHO Guidelines on
Country Pharmaceutical Pricing Policies. WHO.
Geneva. 2015.
